A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia

Authors

  • Selim Ahmed Department of Pharmacology, Sylhet M. A. G. Osmani Medical College, Sylhet 3100
  • A. K. M. Mosharrof Hossain Department of Pharmacology, Sylhet M. A. G. Osmani Medical College, Sylhet 3100
  • Sudhangshu R. Dey Department of Cardiology, Sylhet M.A.G. Osmani Medical College, Sylhet 3100
  • A. K. M. Akhtaruzzaman Department of Cardiology, Sylhet M.A.G. Osmani Medical College, Sylhet 3100
  • Mushammath Morium Siddika Department of Pediatrics, Sylhet M.A.G. Osmani Medical College, Sylhet 3100

DOI:

https://doi.org/10.3329/bjp.v3i1.823

Keywords:

Atorvastatin, Dyslipidemia, Fenofibrate, Niacin

Abstract

The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 mg) either with niacin (1 g) or fenofibrate (200 mg) daily for 12 weeks in 67 coronary heart disease patients with dyslipidemia. There were no significant differences among the two groups (35 patients in Group I and 32 patients in Group II) in serum lipid profile except in level of triglyceride reduction where fenofibrate-atorvastatin combination yielded significant (p<0.001) results. SGPT level significantly raised and fasting blood glucose level decreased in fenofibrate-atorvastatin treated group than niacin-atorvastatin combination. Serum creatinine level decreased in niacin-atorvastatin treated group compared to fenofibrate-atorvastatin, but the changes was within normal limit. This study shows that both combinations are equally effective in dyslipidemia. Although, fenofibrate-atorvastatin combination decreased more triglyceride and niacin-atorvastatin combination appeared safer considering some adverse effects.

Downloads

Download data is not yet available.
Abstract
1075
Download
683 Read
176

References

Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetic Care. 2002; 25: 1198-202.

Barter PJ, Rye KA. Cardioprotective properties of fibrates: Which fibrate, which patients, what mechanism? Circulation 2006; 113: 1553-55.

Bovet P, Shamlaye C, Gabriel A, Riesen W, Paccaud F. Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy. BMC Public Health 2006; 6: 9.

Bruckert E. Epidemiology of low HDL-cholesterol: Results of studies and surveys. Eur Heart J Suppl. 2006; 8F: 17-22.

Chapman MJ, Assmann G, Fruchart JC. Raising high-density cholesterol with reduction of cardiovascular risk: The role of nicotinic acid- A position paper development by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004; 20: 1253-68.

Chockalingam A, Campbell N. Management of hypertension: Diagnosis and lifestyle modification. Indian Heart J. 2005; 57: 639-43.

Davidson M. Statin, fibrate combination therapy: What is the real story? Cardiology Express Report. USA, MMC, Inc., 2003, pp 1-4.

David JN, Chistopher PP. Renal function and nitrogen metabolites. In: Tietz textbook of clinical chemistry. 5th ed. Burtis CA, Ashwood ER (eds). India, Harcourt Brace and Company Asia Ltd, 2001, pp 1241-45.

Deb MR. A comparative study on the effects of atorvastatin administered alone and in combination with ezetimibe in the management of dyslipidemia. MPhil Thesis, Shahjalal University of Science & Technology, Bangladesh, 2006.

Deedwania P, Singh V. Coronary artery disease in South Asians: Evolving strategies for treatment and Prevention. Indian Heart J. 2005; 57: 617-31.

Derosa G, Cicero AE, Bertone G. Comparision of fluvastatin plus fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidaemia, type 2 diabetes mellitus, and coronary heart disease: A 12-month randomized, double-blind, controlled trial. Clin Ther. 2004; 26: 1599-607.

Eckardstein AV. Introduction: New thinking for managing dyslipidemia. Curr Med Res Opin. 2005; 21 S: 1-2.

Fodor JG, Frohlich JJ, Genest JJG Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia. CMAJ. 2000; 162: 1441-47.

Gordon T, Castalli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. Am J Med. 1977; 62: 707-14.

Gowland E. Lipid and lipoprotein. In: Varleys Practical clinical biochemistry. 6th ed. Gowenlock AH (ed). London, Butterworth Heinemann, 1998, pp 452-76.

Grundy SM, Cleeman JI, Merz CNB, Brewer HB JR, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Panel III Guidelines. Circulation 2004; 110: 227-39.

Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, OConnor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998; 82: 737-43.

Handerson AR, Donald WM. Enzymes. In: Tietz textbook of clinical chemistry. 5th ed. Burtis CA, Ashwood ER (eds). India, Harcourt Brace and Company Asia Ltd, 2001, pp 352-89.

Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AFH, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001; 17: 43-50.

Klosiewicz-Latoszek L, Szostak WB, Grzybowska B, Bialobrzeska-Paluszkiewicz J, Wisniewska B, et al. Comparision of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia. Kardiol Pol. 2004; 60: 567-77.

Koh KK, Michael J, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005; 45: 1649-53.

McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in south Asians overseas: A review. J Clin Epidemiol. 1989; 42: 597-609.

McLauchlam DM. Glucose, other sugars and ketone. In: Varley Practical clinical biochemistry. 6th ed. Gowenlock AH (ed). London, Butterworth Heinemann, 1998; pp 320-32.

Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc. 2003; 78: 735-42.

Misra A, Vikram NK, Arya S, Pandey RM, Dhingra V. High prevalence of insulin resistance in post-pubertal Asian Indian children is associated with adverse truncal body fat patterning, abdominal adiposity and excess body fat. Int J Obes Relat Metab Disord. 2004; 28: 1217-26.

Patel JV, Kirby M, Hughes EA. The lipid adults: Analysis of lipid management in two centres in Britain 2003. Br J Cardiol. 2004; 11: 214-17.

Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Rutan GH, et al. Distributions of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 1995; 75: 1196-1201.

Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 2004; 67: 411.

Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2001; 21: 73-79.

Sirtori CR. HDL and the progression of atherosclerosis: New insights. Eur Heart J Suppl. 2006, 8F: 4-9.

Staels B, Auwerx J. Regulation of apoA-1 gene expression by fibrates. Atherosclerosis 1998; 137: 19-23.

Stein EA, Davidson MH, Dujovne CA. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: A prospective trial. J Cardiovasc Pharmacol. 1996; 1: 107-16.

Sultana N, Haque MN, Ali MS, Begum BA, Jahan N, Akter S, et al. A comparative study of body iron status and lipid profile in acute myocardial infarction patients. Mymensingh Med J. 2002; 11: 87-90.

Taylor AJ. Evidence to support aggressive management of HDL-cholesterol: Implications of recent trials. Eur Heart J Suppl. 2006, 8 F: 74-80.

Venkataraman R, Nanda NC, Baweja G, Parikh N, Bhatia V. Prevalence of diabetes mellitus and related conditions in Asian Indians living in the United States. Am J Cardiol. 2004; 94: 977-80.

Watts GF, Dimmitt SB. Fibrate dyslipoproteinemia and cardiovascular disease. Curr Opin Lipid 1999; 10: 561-74.

Wierzbicki AS, Mikhailidis DP, Wray R, Schanchter M, Cramb R, Simpson WA, et al. Statin-fibrate combination therapy for hyperlipidemia: A review. Curr Med Res Opin. 2003; 19: 155-68.

Downloads

Additional Files

Published

2008-04-20

How to Cite

Ahmed, S., A. K. M. M. Hossain, S. R. Dey, A. K. M. Akhtaruzzaman, and M. M. Siddika. “A Comparative Study on the Effects of Niacin Plus Atorvastatin With That of Fenofibrate Plus Atorvastatin in Dyslipidemia”. Bangladesh Journal of Pharmacology, vol. 3, no. 1, Apr. 2008, pp. 8-16, doi:10.3329/bjp.v3i1.823.

Issue

Vol. 3 No. 1 (2008)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).